Table 2 Baseline Demography of the Patient Population
Median age, years [range] | 61 [29–87] |
|---|---|
No. of patients (%) | |
Sex | |
Female | 27 (14) |
Male | 171 (86) |
Primary tumor site | |
Oral cavity | 54 (27) |
Oropharynx | 55 (28) |
Hypopharynx | 47 (24) |
Larynx | 21 (11) |
Other* | 21 (11) |
Tumor stage at initial diagnosis | |
I | 11 (6) |
II | 21 (11) |
III | 23 (12) |
IVa | 106 (54) |
IVb | 16 (8) |
IVc | 13 (7) |
Unknown | 8 (4) |
Initial treatment | |
Neoadjuvant platinum based chemotherapy | 52 (26) |
With Fluorouracil | 43 (22) |
With Taxanes | 41 (21) |
Surgery | 142 (72) |
Radiotherapy | 168 (85) |
Alone | 73 (37) |
With platinum | 74 (37) |
With cetuximab | 20 (10) |
With taxanes | 1 (1) |
Pattern of disease | |
Primary metastatic | 13 (7) |
Primary locally advanced (palliative treatment) | 8 (4) |
Relapse | 177 (89) |
Local only | 126 (63) |
Metastatic +/- local | 51 (26) |
Eligibility for inclusion in a clinical trial | |
Yes | 131 (66) |
No | 67 (34) |
PS ≥ 2 | 53 (27) |
Relapse after initial therapy ≤ 6 months | 27 (14) |
Other concomitant malignancy | 3 (2) |
Major comorbidity | 3 (2) |
PS at onset of palliative chemotherapy | |
0 | 28 (14) |
1 | 117 (59) |
≥ 2 | 53 (27) |